2014

  • Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A, Uyttebroeck A, Sirvent N, Lutz P, Yakouben K, Munzer M, Röhrlich P, Plantaz D, Millot F,Philippet P, Dastugue N, Girard S, Cave’ H, Benoit Y, Bertrand Y.
    Dexamethasone (6 mg/m2/d) and prednisolone (60 mg/m2/d) in induction therapy of childhood acute lymphoblastic leukemia are equally effective in EORTC CLG 58951 randomized trial.
    Haemotologica
  • Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M.
    Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. Patients with CLL and Coexisting Conditions
    NEJM2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
  • – Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G.
    Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily.
    Haematologica.2014 Feb 14
  • Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A.
    Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
    Blood 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. Epub 2013 Dec 11
  • Legros L, Guilhot J, Huault S, Mahon FX, Preudhomme C, Guilhot F, Hueber A; from the French CML Group (FI-LMC).
    Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinibLeukemia
    Research 2014 Feb 1. pii: S0145-2126(14)00028-9. doi: 10.1016/j.leukres.2014.01.010. »
  • Pasmant E, Gilbert-Dussardier B, Petit A, de Laval B, Luscan A, Gruber A, Lapillonne H, Deswarte C, Goussard P, Laurendeau I, Uzan B, Pflumio F, Brizard F, Vabres P, Naguibvena I, Fasola S, Millot F, Porteu F, Vidaud D, Landman-Parker J, Ballerini P.
    SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
    Oncogene.
  • Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G.
    Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
    Blood2014 Apr 10;123(15):2317-24. doi: 10.1182/blood-2013-10-532341. Epub 2014 Feb 25.
  • Tranoy-Opalinski I, Legigan T, Barat R, Clarhaut J, Thomas M, Renoux B, Papot S.
    β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update.
    Eur J Med Chem.
  • Betoko A, Charles MA, Hankard R, Forhan A, Bonet M, Regnault N, Botton J, Saurel-Cubizolles MJ, de Lauzon-Guillain B; EDEN Mother-Child Cohort Study Group.
    Determinants of infant formula use and relation with growth in the first 4 months.
    Matern Child Nutr.
  • de Hauteclocque A, Ragot S, Slaoui Y, Gand E, Miot A, Sosner P, Halimi JM, Zaoui P, Rigalleau V, Roussel R, Saulnier PJ, Hadjadj Samy S;
    The SURDIAGENE Study group. The influence of sex on renal function decline in people with Type 2 diabetes.
    Diabet Med.
  • Fava S, Hadjadj S, Walker J
    Diabetic renal disease. Int J Endocrinol.
  • Mohammedi K, Bellili-Muñoz N, Driss F, Roussel R, Seta N, Fumeron F, Hadjadj S, Marre M, Velho G.Manganese
    Superoxide Dismutase (SOD2)
    Polymorphisms, Plasma Advanced Oxidation Protein Products (AOPP) Concentration and Risk of Kidney Complications in Subjects with Type 1 Diabetes.

    PLoS One. 2014 May 12;9(5):e96916. doi: 10.1371/journal.pone.0096916. eCollection 2014.
  • Saulnier PJ, Gand E, Ragot S, Ducrocq G, Halimi JM, Hulin-Delmotte C, Llaty P, Montaigne D, Rigalleau V, Roussel R, Velho G, Sosner P, Zaoui P, Hadjadj S; SURDIAGENE Study Group
    Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort.
    Diabetes Care2014 May;37(5):1425-31. doi: 10.2337/dc13-2580. Epub 2014 Mar 12
  • Sosner P, Cabasson S, Hulin-Delmotte C, Saulnier PJ, Gand E, Torremocha F, Piguel X, Miot A, Maréchaud R, Herpin D, Ragot S, Hadjadj S; for the SURDIAGENE Study Group.
    Effect of Cornell product and other ECG left ventricular hypertrophy criteria on various cardiovascular endpoints in type 2 diabetic patients.
    Int J Cardiol.2014 Apr 29. pii: S0167-5273(14)00938-3. doi: 10.1016/j.ijcard.2014.04.242.
  • Bauduceau B, Doucet J, Le Floch JP, Verny C; SFD/SFGG Intergroup and the GERODIAB Group.
    Cardiovascular events and geriatric scale scores in elderly (70 years old and above) type 2 diabetic patients at inclusion in the GERODIAB cohort.
    Diabetes Care
  • Welter ML, Schüpbach M, Czernecki V, Karachi C, Fernandez-Vidal S, Golmard JL, Serra G, Navarro S, Welaratne A, Hartmann A, Mesnage V, Pineau F, Cornu P, Pidoux B, Worbe Y, Zikos P, Grabli D, Galanaud D, Bonnet AM, Belaid H, Dormont D, Vidailhet M, Mallet L, Houeto JL, Bardinet E, Yelnik J, Agid Y.
    Optimal target localization for subthalamic stimulation in patients with Parkinson disease.
    Neurology
  • Millet B, Jaafari N, Polosan M, Baup N, Giordana B, Haegelen C, Chabardes S, Fontaine D, Devaux B, Yelnik J, Fossati P, Aouizerate B,Krebs MO, Robert G, Jay T, Cornu P, Vérin M, Drapier S, Drapier D, Sauleau P, Peron J, Jeune FL, Naudet F, Reymann JM.
    Limbic versus cognitive target for deep brain stimulation in treatment-resistant depression: Accumbens more promising than caudate.
    Eur Neuropsychopharmacol.
  • Defossez G, Rollet A, Dameron O, Ingrand P
    Temporal representation of care trajectories of cancer patients using data from a regional information system: an application in breast cancer
    BMC Med Inform Decis Mak2014 Apr 2;14(1):24. doi: 10.1186/1472-6947-14-24
  • Fournier A, Fritel X, Panjo H, Zins M, Ringa V.
    Health characteristics of women beginning postmenopausal hormone therapy: have they changed since the publication of the Women’s Health Initiative?
    Menopause 2013 Dec 30. [Epub ahead of print]
  • Ragot S, Sosner P, Dievart F, Herpin D.
    Prevalence and management of uncontrolled hypertension in French patients aged over 80 years.
    Arch Cardiovasc Dis.
  • Ramful D, Sampériz S, Fritel X, Michault A, Jaffar-Bandjee MC, Rollot O, Boumahni B, Gérardin P
    Antibody Kinetics in Infants Exposed to Chikungunya Virus Infection During Pregnancy Reveals Absence of Congenital Infection
    J Infect Dis2014 Jan 14. [Epub ahead of print]
  • Savelli M, Boura E, De Luca A, Thomas A, Retaud F, Dupuis Ferber J, Rousseau B, Rauby A, George C, Cugny M, Louis S, Hankard R.
    BMI below the third centile in 4-year-old children
    Archives Pédiatriques2014 May;21(5):544-5. doi: 10.1016/j.arcped.2014.02.017. Epub 2014 Mar 31
  • Sibai MS, Bellarbre F, Ghazali N, Bureau ML, Priner M, Ingrand P, Paccalin M
    Decisional algorithm to prescribe vitamin K antagonist in geriatric patients with atrial fibrillation.
    Geriatr Psychol Neuropsychiatr Vieil.
  • Tripon C, Defossez G, Ragot S, Ghazali A, Boureau-Voultoury A, Scépi M, Oriot D.
    Parental presence during cardiopulmonary resuscitation of children: the experience, opinions and moralpositions of emergency teams in France.
    Arch Dis Child
  • Bridoux A, Thille AW, Quentin S, Lode-Kolz K, Stal V, Diaz V, Brochard L, Drouot X
    Sleep in ICU: atypical sleep or atypical electroencephalography?
    Crit Care Med. 2014  2014 Apr;42(4):e312-3. doi: 10.1097/CCM.0000000000000158.